73 results
Page 2 of 4
6-K
EX-99.2
2yx3lh
22 Nov 21
Obseva Announces U.S. FDA Acceptance of New Drug Application for Linzagolix
6:05am
F-3
3by h9op1
10 Nov 21
Shelf registration (foreign)
5:23pm
6-K
EX-99.2
p8dl4e
4 Nov 21
Index to Unaudited Condensed Consolidated Financial Statements
7:21am
6-K/A
EX-99.2
ft1nt
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K/A
EX-99.5
lka78trs 6pz
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
5:24pm
6-K
EX-99.2
ufdz53gbaeu49k qp
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.5
jbpfve28a3ofk5pzxtb7
13 Oct 21
ObsEva Announces Relationship with Syneos Health to Commercialize Linzagolix
9:27am
6-K
EX-99.2
kbmhak6ha5
5 Aug 21
Index to Unaudited Condensed Consolidated Financial Statements
6:04am
6-K
EX-99.1
c1vm22jl8 pvuq85
1 Jun 21
ObsEva SA Announces that Shareholders Approved all Board Proposals at its
6:30am
6-K
EX-99.2
3zi vjf4o
6 May 21
Index to Unaudited Condensed Consolidated Financial Statements
6:03am
6-K
EX-99.1
hr2li3w0b7
22 Apr 21
ObsEva Annual General Meeting 2021
6:31am
6-K
EX-1.1
sfa9g5jb3tw8ywwdtt
5 Mar 21
Current report (foreign)
8:15am
424B5
bvfe5mrywa4g21r7v ud
5 Mar 21
Prospectus supplement for primary offering
7:55am
6-K
EX-99.1
sin3abp88su4
5 Mar 21
ObsEva Announces Year End 2020 Financial Results
7:21am
6-K
EX-1.1
iekba t2p
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
6-K
EX-10.1
6q2y h9w8f3f
8 Sep 20
ObsEva Announces $20.0 Million Underwritten Offering and Concurrent Private Placement
7:40am
424B5
wkzbq5md plzu
8 Sep 20
Prospectus supplement for primary offering
7:31am
6-K
0w13n8shc48vict7v49
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am
6-K
EX-99.2
8rjgf p5z
6 Aug 20
Index to Unaudited Condensed Consolidated Financial Statements
6:53am